Home LiteratureArticle Details
PMID: 17604869 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Hepatitis C virus RNA: dinucleotide frequencies and cleavage by RNase L.

Virus research ·Vol. 130 ·No. 1-2 ·2007-12-00 ·Pages 85-95

Washenberger CL, Han JQ, Kechris KJ, Jha BK, Silverman RH, Barton DJ

Abstract

Ribonuclease L (RNase L) is an antiviral endoribonuclease that cleaves hepatitis C virus (HCV) RNA at single-stranded UA and UU dinucleotides throughout the open reading frame (ORF). To determine whether RNase L exerts evolutionary pressure on HCV we examined the frequencies of UA and UU dinucleotides in 162 RNA sequences from the Los Alamos National Labs HCV Database (http://hcv.lanl.gov). Considering the base composition of the HCV ORFs, both UA and UU dinucleotides were less frequent than predicted in each of 162 HCV RNAs. UA dinucleotides were significantly less frequent than predicted at each of the three codon positions while UU dinucleotides were less frequent than predicted predominantly at the wobble position of codons. UA and UU dinucleotides were among the least abundant dinucleotides in HCV RNA ORFs. Furthermore, HCV genotype 1 RNAs have a lower frequency of UA and UU dinucleotides than genotype 2 and 3 RNAs, perhaps contributing to increased resistance of HCV genotype 1 infections to interferon therapy. In vitro, RNase L cleaved both HCV genotype 1 and 2 RNAs efficiently. Thus, RNase L can cleave HCV RNAs efficiently and variably reduced frequencies of UA and UU dinucleotides in HCV RNA ORFs are consistent with the selective pressure of RNase L.

MeSH Terms
Base Composition/genetics Codon/genetics Dinucleoside Phosphates/genetics Endoribonucleases/immunology,metabolism Hepacivirus/genetics,immunology RNA, Viral/genetics,metabolism Selection, Genetic
Chemicals
Codon Dinucleoside Phosphates RNA, Viral Endoribonucleases 2-5A-dependent ribonuclease
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Washenberger Christopher L
Department of Microbiology, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045, United States.
Han Jian-Qiu
Kechris Katherina J
Jha Babal Kant
Silverman Robert H
Barton David J
References (65)
65 references, click to expand
  1. The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation.
    Pharmacol Ther. 1998 May;78(2):55-113 PMID: 9623881
  2. Tissue-specific codon usage and the expression of human genes.
    Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12588-91 PMID: 15314228
  3. Monitoring activation of ribonuclease L by 2',5'-oligoadenylates using purified recombinant enzyme and intact malignant glioma cells.
    Methods Enzymol. 2001;342:10-20 PMID: 11586885
  4. Detection of a novel unglycosylated form of hepatitis C virus E2 envelope protein that is located in the cytosol and interacts with PKR.
    J Virol. 2002 Feb;76(3):1265-72 PMID: 11773402
  5. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.
    Hepatology. 2003 Sep;38(3):645-52 PMID: 12939591
  6. Genetic diversity and evolution of hepatitis C virus--15 years on.
    J Gen Virol. 2004 Nov;85(Pt 11):3173-88 PMID: 15483230
  7. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
    N Engl J Med. 1998 Nov 19;339(21):1485-92 PMID: 9819446
  8. Retention and repression: fates of hyperedited RNAs in the nucleus.
    Curr Opin Cell Biol. 2005 Jun;17(3):302-8 PMID: 15901501
  9. Hepatitis C virus: an infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras.
    Virology. 1999 Sep 15;262(1):250-63 PMID: 10489358
  10. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling.
    Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2986-91 PMID: 15710892
  11. Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin.
    Liver Int. 2003 Dec;23(6):426-33 PMID: 14986817
  12. A cis-acting replication element in the sequence encoding the NS5B RNA-dependent RNA polymerase is required for hepatitis C virus RNA replication.
    J Virol. 2004 Feb;78(3):1352-66 PMID: 14722290
  13. Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response.
    J Infect Dis. 2000 Feb;181(2):432-41 PMID: 10669323
  14. Assays for poliovirus polymerase, 3D(Pol), and authentic RNA replication in HeLa S10 extracts.
    Methods Enzymol. 1996;275:35-57 PMID: 9026649
  15. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates.
    Science. 2006 Nov 10;314(5801):997-1001 PMID: 17038589
  16. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA.
    Science. 1997 Jul 25;277(5325):570-4 PMID: 9228008
  17. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
    Lancet. 2001 Sep 22;358(9286):958-65 PMID: 11583749
  18. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation.
    Mol Cell Biol. 1998 Sep;18(9):5208-18 PMID: 9710605
  19. Activation and evasion of the antiviral 2'-5' oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA.
    RNA. 2002 Apr;8(4):512-25 PMID: 11991644
  20. A target on the move: innate and adaptive immune escape strategies of hepatitis C virus.
    Antiviral Res. 2006 Mar;69(3):129-41 PMID: 16413618
  21. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy.
    J Viral Hepat. 2001 Nov;8(6):414-20 PMID: 11703572
  22. Evolution of the genome and the genetic code: selection at the dinucleotide level by methylation and polyribonucleotide cleavage.
    Proc Natl Acad Sci U S A. 1989 Jan;86(1):192-6 PMID: 2463621
  23. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease.
    Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15661-8 PMID: 12441397
  24. A phylogenetically conserved RNA structure in the poliovirus open reading frame inhibits the antiviral endoribonuclease RNase L.
    J Virol. 2007 Jun;81(11):5561-72 PMID: 17344297
  25. 5'-Triphosphate RNA is the ligand for RIG-I.
    Science. 2006 Nov 10;314(5801):994-7 PMID: 17038590
  26. Basis for regulated RNA cleavage by functional analysis of RNase L and Ire1p.
    RNA. 2001 Mar;7(3):361-73 PMID: 11333017
  27. GB virus C/hepatitis G virus infection in chronic hepatitis C patients with and without interferon-alpha therapy.
    Antiviral Res. 2001 Dec;52(3):241-9 PMID: 11675141
  28. Structural basis for recognition of 2',5'-linked oligoadenylates by human ribonuclease L.
    EMBO J. 2004 Oct 13;23(20):3929-38 PMID: 15385955
  29. Detection of genome-scale ordered RNA structure (GORS) in genomes of positive-stranded RNA viruses: Implications for virus evolution and host persistence.
    RNA. 2004 Sep;10(9):1337-51 PMID: 15273323
  30. Structural constraints on RNA virus evolution.
    J Virol. 1999 Jul;73(7):5787-94 PMID: 10364330
  31. CARD games between virus and host get a new player.
    Trends Immunol. 2006 Jan;27(1):1-4 PMID: 16309964
  32. Mapping of the human RNASEL promoter and expression in cancer and normal cells.
    J Interferon Cytokine Res. 2005 Oct;25(10):595-603 PMID: 16241858
  33. EMBOSS: the European Molecular Biology Open Software Suite.
    Trends Genet. 2000 Jun;16(6):276-7 PMID: 10827456
  34. Hepatitis C and G co-infection: response to interferon therapy and quantitative changes in serum HGV-RNA.
    Hepatology. 1997 Nov;26(5):1322-7 PMID: 9362379
  35. Amino acid substitutions in PKR-eIF2 phosphorylation homology domain (PePHD) of hepatitis C virus E2 protein in genotype 2a/2b and 1b in Japan and interferon efficacy.
    Hepatol Res. 2003 Aug;26(4):268-274 PMID: 12963425
  36. The large form of ADAR 1 is responsible for enhanced hepatitis delta virus RNA editing in interferon-alpha-stimulated host cells.
    J Viral Hepat. 2006 Mar;13(3):150-7 PMID: 16475990
  37. The extent of codon usage bias in human RNA viruses and its evolutionary origin.
    Virus Res. 2003 Mar;92(1):1-7 PMID: 12606071
  38. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein.
    Science. 1999 Jul 2;285(5424):107-10 PMID: 10390359
  39. Evasion of intracellular host defence by hepatitis C virus.
    Nature. 2005 Aug 18;436(7053):939-45 PMID: 16107833
  40. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection.
    Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):6001-6 PMID: 16585524
  41. Hepatitis C virus envelope protein E2 does not inhibit PKR by simple competition with autophosphorylation sites in the RNA-binding domain.
    J Virol. 2001 Feb;75(3):1265-73 PMID: 11152499
  42. Poliovirus CRE-dependent VPg uridylylation is required for positive-strand RNA synthesis but not for negative-strand RNA synthesis.
    J Virol. 2003 Apr;77(8):4739-50 PMID: 12663781
  43. Hearing silence: non-neutral evolution at synonymous sites in mammals.
    Nat Rev Genet. 2006 Feb;7(2):98-108 PMID: 16418745
  44. RNA editing in hepatitis delta virus genotype III requires a branched double-hairpin RNA structure.
    J Virol. 2002 Aug;76(15):7385-97 PMID: 12097551
  45. Cytopathic and noncytopathic interferon responses in cells expressing hepatitis C virus subgenomic replicons.
    J Virol. 2003 Oct;77(20):10769-79 PMID: 14512527
  46. Characteristics of nucleotide substitution in the hepatitis C virus genome: constraints on sequence change in coding regions at both ends of the genome.
    J Mol Evol. 1997 Sep;45(3):238-46 PMID: 9302317
  47. Interferon action and apoptosis are defective in mice devoid of 2',5'-oligoadenylate-dependent RNase L.
    EMBO J. 1997 Nov 3;16(21):6355-63 PMID: 9351818
  48. Efficacy of ribavirin plus interferon alpha on viraemia of GB virus-C/hepatitis G virus: comparison with interferon alpha alone.
    J Gastroenterol Hepatol. 1998 Dec;13(12):1249-53 PMID: 9918434
  49. Sensitivity of hepatitis C virus RNA to the antiviral enzyme ribonuclease L is determined by a subset of efficient cleavage sites.
    J Interferon Cytokine Res. 2004 Nov;24(11):664-76 PMID: 15684820
  50. Hepatitis delta virus minimal substrates competent for editing by ADAR1 and ADAR2.
    J Virol. 2001 Sep;75(18):8547-55 PMID: 11507200
  51. Coupled translation and replication of poliovirus RNA in vitro: synthesis of functional 3D polymerase and infectious virus.
    J Virol. 1993 Feb;67(2):822-31 PMID: 8380467
  52. Cardif: a protein central to innate immunity is inactivated by the HCV NS3 serine protease.
    Hepatology. 2006 Mar;43(3):615-7 PMID: 16496328
  53. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region.
    J Clin Invest. 1995 Jul;96(1):224-30 PMID: 7542279
  54. Epidemiology of hepatitis C.
    Hepatology. 1997 Sep;26(3 Suppl 1):62S-65S PMID: 9305666
  55. Dinucleotide and stop codon frequencies in single-stranded RNA viruses.
    J Gen Virol. 1997 Nov;78 ( Pt 11):2859-70 PMID: 9367373
  56. Correlation of interferon treatment response with GBV-C/HGV genomic RNA and anti-envelope 2 protein antibody.
    J Med Virol. 1999 Apr;57(4):370-5 PMID: 10089049
  57. The Los Alamos hepatitis C sequence database.
    Bioinformatics. 2005 Feb 1;21(3):379-84 PMID: 15377502
  58. Effect of alpha interferon on the hepatitis C virus replicon.
    J Virol. 2001 Sep;75(18):8516-23 PMID: 11507197
  59. The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease.
    N Engl J Med. 1997 Mar 13;336(11):747-54 PMID: 9052652
  60. Selective RNA cleavage by isolated RNase L activated with 2-5A antisense chimeric oligonucleotides.
    Methods Enzymol. 2000;313:522-33 PMID: 10595377
  61. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus.
    Nature. 2005 Oct 20;437(7062):1167-72 PMID: 16177806
  62. Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy.
    J Viral Hepat. 2005 Sep;12(5):465-72 PMID: 16108760
  63. Complete replication of poliovirus in vitro: preinitiation RNA replication complexes require soluble cellular factors for the synthesis of VPg-linked RNA.
    J Virol. 1995 Sep;69(9):5516-27 PMID: 7636997
  64. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.
    Ann Intern Med. 2006 May 16;144(10):705-14 PMID: 16702586
  65. Retroviral restriction by APOBEC proteins.
    Nat Rev Immunol. 2004 Nov;4(11):868-77 PMID: 15516966
Article Info
Journal
Virus research
Abbr.
Virus Res
ISSN
0168-1702
Published
2007-12-00
Epub
2007-00-02
Pages
85-95
Language
English
Region
Netherlands
NLM ID
8410979
PMCID
PMC2186174
Subset
IM
Grants
NCI NIH HHS · R01 CA044059 · United States
NCI NIH HHS · R01 CA044059-23 · United States
NCI NIH HHS · CA-44059 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]